Oury Chetboun, Founder and CEO at Seekyo Therapeutics, shared a post on LinkedIn:
“Tumor Activated Therapy (TAT) doesn’t negotiate with the tumor’s escape mechanisms.
ADCs rely on antigen expression – and tumor heterogeneity breaks them. The more we push them, the more their structural constraints show.
Seekyo Therapeutics’ TAT takes a fundamentally different route. Instead of antigen-dependent internalization, TAT exploits β-Glucuronidase – an enzyme overexpressed in the extracellular tumor microenvironment – to trigger payload activation directly at the tumor site.
- No antigen required.
- Broad payload diffusion.
- Heterogeneity-resistant by design.
This extracellular enzymatic logic has shown consistent preclinical efficacy across pancreatic, TNBC and even glioblastoma cancers.
Precision goes one step further with Seekyo Therapeutics’ Induced Volatolomics- VOC probes that detect β-Glucuronidase presence and activity in the TME before treatment begins. Patient stratification happens upstream, not after the first cycle.
The question I keep coming back to: in solid tumor oncology, should enzymatic activation – rather than antigen targeting – become the new standard for patient selection?”
Other articles about Immunotherapy on OncoDaily.